Hospitalization rates for heart fai...

Hospitalization rates for heart failure are high, and six-month readmission rates approach 50 percent Because book expansion often leads to exacerbation, diuretics are the mainstay of therapy, moreover these drugs can have adverse powers and do not prolong survival. A medication that stops arginine-vasopressin might have long-term pharmacologic benefits similar to those of other medications for congestive heart failure (CHF) like as angiotensin-converting enzyme inhibitors and beta blocker further it also may have an added benefit of relieving bulk overload and congestion immediately when combined with diuretics. In this subject of attention Gheorghiade and colleagues compared the vasopressin V2 receptor antagonist tolvaptan with placebo in the usual acute care of patients hospitalized for CHF

In the double-blind, controll Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) trial, patients 18 years or older with CHF and an ejection fraction of les than 40 percent were randomized to common of three doses (i.e., 30 60 or 90 mg) of tolvaptan or placebo, with all clusters receiving concomitant standard care, including diuretics. The primary issues included acute (in-hospital) and intermediate-term (outpatient and after discharge) weights of tolvaptan. Acute effects were measured by dint of changes in body weight after 24 hours following the first ingestion of the put drugs into Intermediate effects were measured at readmission, or urgent clinic or pass department visits resulting in more intensive therapy or a change in therapy 60 days after randomization, indicating worsening heart failure. Other cessation points included secondary symptoms and laboratory abnormalities.

Of the 319 patients enlisted a significantly greater body weight reduction was observ in the tolvaptan clusters compared with the placebo cluster during the first day of hospitalization. This change was greater in the treatment clusters from baseline to discharge compared with the placebo-treated assign places to All patients lost weight and had improved symptoms during this phase; solely dyspnea was improved significantly in the tolvaptan assign places to at discharge. In the outpatient phase, there was no significant difference between treatment and placebo clumps in worsening heart failure. A post-hoc analysis showed that event-free survival keeped to be longer in the combined tolvaptan form into groupss compared with placebo, with a lower total mortality in the chiefly severe subgroups. Tolvaptan was well tolerated, moreover it caused thirst in a large percentage of patients.

This investigation showed improvements with tolvaptan in the acute phase in patients with CHF with greater book loss in treated patients than in those given placebo, confirming tolvaptan's potential advantage--although it has even now to show clinical benefit--of rapid action. The studious mood was not designed to measure mortality, if it were not that a post-hoc analysis found a stretch toward lower mortality in the chiefly severely affected patients taking tolvaptan. This finding would require corroboration at studies focused on mortality outcomes

Gheorghiade M et al. general intents of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. A randomized controll trial. JAMA April 28 2004;291:1963-71

COPYRIGHT 2005 American Academy of Family Physicians

COPYRIGHT 2005 Gale Group